Table 1 Comparison of baseline characteristics of patients
Unmatched cohort (n = 192) | Propensity matched cohort (n = 92) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
N | Cardiac surgery, n = 125 | N | No surgery, n = 67 | p | N | Cardiac surgery, n = 44 | N | No surgery, n = 44 | p | |
Age*, yr median (IQR) | 125 | 62 (48–67) | 67 | 65 (50–73.5) | 0,10 | 44 | 65 (16.5) | 44 | 64.5 (22) | 0.56 |
Male*, n (%) | 125 | 89 (71.2%) | 67 | 44 (65.7%) | 0,43 | 44 | 29 (65.9%) | 44 | 28 (63.6%) | 1.0 |
Preexisting medical conditions, n (%) | ||||||||||
Diabetes mellitus, n (%) | 125 | 34 (27.2%) | 67 | 17 (25.4%) | 0,78 | 44 | 16 (36.4%) | 44 | 10 (22.7%) | 0,24 |
Chronic kidney disease, n (%) | 125 | 48 (38.4%) | 67 | 28 (41.8%) | 0,65 | 44 | 12 (27.2%) | 44 | 8 (18.2%) | 0.52 |
Immunosuppression, n (%) | 125 | 10 (8%) | 67 | 11 (16.4%) | 0,07 | 44 | 5 (11.4%) | 44 | 6 (13.6%) | 0,12 |
Valve prosthesis*, n (%) | 125 | 26 (20.8%) | 67 | 24 (35.8%) | 0,02 | 44 | 13 (29.5%) | 44 | 11 (25.0%) | 0,81 |
Bacteriological characteristics, n (%) | ||||||||||
Positive blood cultures, n (%) | 125 | 116 (92.8%) | 67 | 58 (86.6%) | 0,16 | 44 | 42 (95.5%) | 44 | 38 (86.4%) | 0,43 |
Positive valve culture, n (%) | 101 | 35 (34.7%) | 67 | – | – | 33 | 19 (51.4%) | 0 | – | – |
Isolated bacterial specie | 125 | 67 | 0.39 | 44 | 44 | 0.20 | ||||
Staphylococcus sp. | 67 (53.6%) | 37 (55.2%) | 20 (48.8%) | 22 (59.5%) | 0.20 | |||||
- MSSA | 57 (45.6%) | 30 (44.8%) | 18 (43.9%) | 20 (54.1%) | ||||||
- MRSA | 5 (4%) | 4 (6%) | 2 (4.9%) | 2 (5.4%) | ||||||
- Others | 5 (4%) | 3 (4.5%) | 1 (2.4%) | 1 (2.7%) | ||||||
Streptococcus sp. | 32 (26%) | 10 (15%) | 10 (24.4%) | 5 (13.5%) | ||||||
Enterobacterales | 10 (8%) | 9 (13.4%) | 4 (9.5%) | 6 (15.8%) | ||||||
Others (Enterococcus sp., …) | 14 (11.2%) | 4 (6%) | 4 (9.8%) | 4 (10.8%) | ||||||
Health-care acquired endocarditis, n (%) | 125 | 25 (20%) | 67 | 20 (29.9%) | 0.12 | 44 | 13 (29.5%) | 44 | 14 (31.8%) | 1.00 |
Valve damage | ||||||||||
Valve damage, n (%)* | 125 | 67 | 0.74 | 44 | 44 | 0.50 | ||||
- Mitral and aortic | 24 (19%) | 16 (24%) | 9 (20.5%) | 5 (11.4%) | ||||||
- Mitral | 45 (36%) | 22 (33%) | 16 (36.4%) | 17 (38.6%) | ||||||
- Aortic | 56 (45%) | 29 (43%) | 19 (43.2%) | 22 (50.0%) | ||||||
Medical condition at admission to ICU | ||||||||||
EuroSCORE mean ± SD | 125 | 17 ± 17 | 67 | 25 ± 18 | 0.003 | 44 | 20 ± 20 | 44 | 21.5 ± 17 | 0.74 |
SOFA score*, median (IQR) | 125 | 6 (4–9) | 67 | 9 (6–13) | < 0.001 | 44 | 6 (6) | 44 | 7.5 (7) | 0.24 |
LVEF %, mean ± SD | 125 | 58 ± 10 | 67 | 52 ± 13 | 0.001 | 44 | 58 ± 8 | 44 | 54 ± 13 | 0.07 |
Lowest Glasgow score, median (IQR) | 125 | 14 (13–15) | 67 | 11 (6–14) | < 0.001 | 44 | 14 (2.5) | 44 | 11.5 (6.2) | 0.03 |
Glasgow < 10, n (%) | 125 | 21 (17%) | 67 | 29 (43%) | < 0.001 | 44 | 17 (39%) | 44 | 9 (21%) | 0.07 |
Killip score, median (IQR) | 114 | 2 (1–3) | 63 | 2 (1–2.5) | 0.32 | 41 | 1 (2) | 44 | 2 (2) | 0.78 |
Septic shock*, n (%) | 125 | 28 (22.4%) | 67 | 31 (46.3%) | 0.001 | 44 | 16 (36.4%) | 44 | 19 (43.2%) | 0.66 |
Cardiogenic shock, n (%) | 125 | 20 (16%) | 67 | 14 (20.9%) | 0.40 | 44 | 7 (15.9%) | 44 | 11 (25%) | 0.43 |
Extra neurological localizations, n (%) | ||||||||||
Extra cerebral localization | 125 | 110 (88%) | 67 | 66 (98.5%) | 0,01 | 44 | 44 (100%) | 44 | 44 (100%) | 1.0 |
Primary antimicrobial therapy, n (%) | ||||||||||
Adequate, n (%) | 117 | 112 (95.7%) | 58 | 57 (98.3%) | 0,38 | 41 | 38 (93%) | 38 | 37 (97%) | 0.61 |
Aminoglycoside, n (%) | 125 | 105 (84%) | 66 | 55 (83.3%) | 0,90 | 44 | 35 (79%) | 43 | 37 (86%) | 0.60 |